Palo Alto, CA, United States of America

Nicholas M Valiante

This inventor holds 1 USPTO granted patent. Top assignee: The Wistar Institute. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas M Valiante. Retrieved from https://idiyas.com/inventor/nicholas-m-valiante-d2s92wxy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Nicholas M Valiante

Introduction

Nicholas M Valiante is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of immunology through his innovative research and inventions. His work primarily focuses on the development of novel therapeutic agents that can enhance immune responses.

Latest Patents

Nicholas M Valiante holds a patent for a human cytotoxic lymphocyte signal transduction surface protein known as p38. The patent describes a novel monoclonal antibody, mAb C1.7, which acts as an activating structure for NK cells and CD8+ T cells. This invention provides methods for using these compositions to identify and monitor diseases, as well as for therapeutic purposes. He has 1 patent to his name.

Career Highlights

Valiante's career has been marked by his dedication to advancing the understanding of immune mechanisms. His work has implications for developing new treatments for various diseases, particularly those involving immune system dysfunction.

Collaborations

One of his notable collaborators is Giorgio Trinchieri, with whom he has worked on various research projects aimed at enhancing immune responses.

Conclusion

Nicholas M Valiante's contributions to immunology through his patent and research collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for innovative therapeutic approaches.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…